Engineered Cationic Antimicrobial Peptides To Overcome Multidrug Resistance by ESKAPE Pathogens

被引：104
作者：
Deslouches, Berthony [1 ,2 ]
Steckbeck, Jonathan D. [1 ,2 ]
Craigo, Jodi K. [1 ,2 ]
Doi, Yohei [3 ]
Burns, Jane L. [4 ]
Montelaro, Ronald C. [1 ,2 ]
机构：
[1] Univ Pittsburgh, Sch Med, Ctr Vaccine Res, Pittsburgh, PA 15260 USA
[2] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA
[3] Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA 15213 USA
[4] Seattle Childrens Res Inst, Div Pediat Infect Dis, Seattle, WA USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2015年 / 59卷 / 02期
关键词：
ANTIBIOTIC-PROPHYLAXIS; PSEUDOMONAS-AERUGINOSA; COLISTIN-RESISTANT; NO ESKAPE; TRYPTOPHAN; GUIDELINE; INFECTION; PARADIGM; BACTERIA; SURGERY;
D O I：
10.1128/AAC.03937-14
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Multidrug resistance constitutes a threat to the medical achievements of the last 50 years. In this study, we demonstrated the abilities of two de novo engineered cationic antibiotic peptides (eCAPs), WLBU2 and WR12, to overcome resistance from 142 clinical isolates representing the most common multidrug-resistant (MDR) pathogens and to display a lower propensity to select for resistant bacteria in vitro compared to that with colistin and LL37. The results warrant an exploration of eCAPs for use in clinical settings.
引用
收藏
页码：1329 / 1333
页数：5
相关论文
共 33 条
[1]   A Paradigm Shift in Drug Development for Treatment of Rare Multidrug-Resistant Gram-Negative Pathogens [J].
Alemayehu, Demissie ;
Quinn, John ;
Cook, Jack ;
Kunkel, Mark ;
Knirsch, Charles A. .
CLINICAL INFECTIOUS DISEASES, 2012, 55 (04) :562-567
[2]   Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America [J].
Boucher, Helen W. ;
Talbot, George H. ;
Bradley, John S. ;
Edwards, John E., Jr. ;
Gilbert, David ;
Rice, Louis B. ;
Scheld, Michael ;
Spellberg, Brad ;
Bartlett, John .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) :1-12
[3]   There should be no ESKAPE for febrile neutropenic cancer patients: the dearth of effective antibacterial drugs threatens anticancer efficacy [J].
Bow, E. J. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (03) :492-495
[4]   Impact of LL-37 on anti-infective immunity [J].
Bowdish, DME ;
Davidson, DJ ;
Lau, YE ;
Lee, K ;
Scott, MG ;
Hancock, REW .
JOURNAL OF LEUKOCYTE BIOLOGY, 2005, 77 (04) :451-459
[5]   Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? [J].
Brogden, KA .
NATURE REVIEWS MICROBIOLOGY, 2005, 3 (03) :238-250
[6]   Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood:: Implications for systemic applications [J].
Deslouches, B ;
Islam, K ;
Craigo, JK ;
Paranjape, SM ;
Montelaro, RC ;
Mietzner, TA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) :3208-3216
[7]   De nova generation of cationic antimicrobial peptides: Influence of length and tryptophan substitution on antimicrobial activity [J].
Deslouches, B ;
Phadke, SM ;
Lazarevic, V ;
Cascio, M ;
Islam, K ;
Montelaro, RC ;
Mietzner, TA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (01) :316-322
[8]   De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia [J].
Deslouches, Berthony ;
Gonzalez, Ivan A. ;
DeAlmeida, Dilhari ;
Islam, Kazi ;
Steele, Chad ;
Montelaro, Ronald C. ;
Mietzner, Timothy A. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (03) :669-672
[9]   Rational Design of Engineered Cationic Antimicrobial Peptides Consisting Exclusively of Arginine and Tryptophan, and Their Activity against Multidrug-Resistant Pathogens [J].
Deslouches, Berthony ;
Steckbeck, Jonathan D. ;
Craigo, Jodi K. ;
Doi, Yohei ;
Mietzner, Timothy A. ;
Montelaro, Ronald C. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (06) :2511-2521
[10]   Alternative mechanisms of action of cationic antimicrobial peptides on bacteria [J].
Hale, John D. F. ;
Hancock, Robert E. W. .
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2007, 5 (06) :951-959
1234